Daiichi Sankyo
AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics
October 31, 2025AAX Biotech, Daiichi Sankyo, Opti-mAb, Seqitope
AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic partnership with Daiichi Sankyo, a …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
August 7, 2024Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …
AstraZeneca shares results from phase 3 TROPION-Lung01 trial
May 28, 2024Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
April 2, 2024Research and Development AstraZeneca, Daiichi Sankyo, FDA, Oncology, bla, breast cancer
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan (Dato-Dxd) has been accepted in …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
March 4, 2024Medical Communications CHMP, Daiichi Sankyo, EMA, Oncology, datopotamab deruxtecan
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications (MAAs) for AstraZeneca and Daiichi …
Daiichi Sankyo shares results for Ezharmia as lymphoma treatment
December 11, 2023Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma
Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful …
Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment
November 10, 2023Medical Communications Daiichi Sankyo, EC, EU, Oncology, Vanflyta, acute myeloid leukaemia
Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination use with standard cytarabine and …
AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC
October 23, 2023Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology
AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial
September 22, 2023Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial
AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) …
AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial
September 11, 2023Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial
AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …
Daiichi Sankyo’s Enhertu approved in Japan as treatment for metastatic NSCLC
August 23, 2023Medical Communications Daiichi Sankyo, Enhertu, Japan's MHLW, NSCLC, Oncology, trastuzumab deruxtecan
Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with …
NICE recommends Daiichi Sankyo’s cholesterol-lowering treatments for NHS England use
March 18, 2021Daiichi Sankyo, NICE, cholesterol
NICE has recommended Daiichi Sankyo’s bempedoic acid and bempedoic acid/ezetimibe for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed …
Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu approved in UK
February 16, 2021Manufacturing and Production AstraZeneca, Cancer, Daiichi Sankyo
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted conditional authorisation in the UK as a monotherapy for the …
EU approves breast cancer drug Enhertu
January 20, 2021Research and Development AstraZeneca, Daiichi Sankyo
The EU has granted AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) conditional approval as a monotherapy for the treatment of …
Daiichi Sankyo’s Nilemdo “significantly” reduces cholesterol levels at ESC 2020
September 1, 2020Manufacturing and Production, Research and Development Daiichi Sankyo, Nilemdo, pharma
Daiichi Sankyo has unveiled promising new benefit for Nilemdo (bempedoic acid) at the ESC Congress 2020 over the weekend for …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
